To evaluate the clinical and functional effects of using orthobiological therapies (hyaluronic acid, platelet-rich plasma, bone marrow aspirate, nanofat, among others) in the treatment of various musculoskeletal diseases in patients routinely treated at the Proregen Medical Clinic and its affiliates.

The sample will consist of adult patients (≥18 years), of both sexes, with different musculoskeletal diagnoses involving joints, tendons, ligaments, cartilage or bone, among others.

Orthobiological therapies, such as hyaluronic acid, platelet-rich plasma, bone marrow aspirate concentrate, and adipose tissue derivatives, have been widely used in the management of musculoskeletal pathologies, including tendinopathies, osteoarthritis, and delayed bone consolidation. However, scientific evidence is still limited by the heterogeneity of protocols, populations, and evaluation methods. This umbrella project aims to prospectively record and analyze the clinical and functional outcomes associated with the use of these therapies in patients treated according to institutional medical indications. Participants with different osteoarticular pathologies undergoing routine orthobiological treatment at the Proregen Medical Clinic and its affiliates will be included. The central hypotheses of the study are that orthobiological therapies present measurable clinical benefits in terms of pain, function, and quality of life in various osteoarticular indications; that the safety of these approaches is adequate when performed under defined clinical criteria; and that it is possible to identify patterns of greater efficacy according to the type of orthobiological agent, the pathology, and the follow-up time. As an expected conclusion, the study aims to generate real clinical data that can serve as a basis for derivative studies, in addition to contributing to the standardization and rationalization of the use of orthobiological therapies in orthopedic practice.

Inclusion Criteria:

• Age 18 or older;
• Clinical and/or radiological diagnosis of an eligible musculoskeletal condition;
• Formal clinical indication for treatment with orthobiological agents, according to routine care;
• Regular access to the WhatsApp application, ensuring the necessary communication for sending and receiving digital questionnaires and other study instructions;
• Ability to understand the study and sign the Informed Consent Form.

Exclusion Criteria:

• Medical contraindication to the use of orthobiologics (e.g., active infection, severe hematological diseases, active cancer);
• Recent use (≤3 months) of orthobiologic therapies in the same area to be treated;
• Pregnant or breastfeeding women;
• Cognitive or psychiatric diseases that prevent adequate clinical follow-up;
• Simultaneous participation in another interventional clinical study with the same therapeutic purpose.

We cannot yet provide this information, as the study involves a larger team.